Marker Therapeutics, Inc.
MRKR
$1.27
$0.086.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -12.99% | 44.55% | 71.52% | 99.06% | 79.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.99% | 44.55% | 71.52% | 99.06% | 79.04% |
| Cost of Revenue | 64.64% | 29.55% | 9.82% | -4.01% | -24.56% |
| Gross Profit | -260.83% | -19.98% | 22.73% | 52.03% | 69.36% |
| SG&A Expenses | -4.93% | -18.52% | -32.69% | -43.26% | -40.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.57% | 36.30% | 14.12% | -1.02% | -11.90% |
| Operating Income | -41.39% | -33.50% | 0.75% | 23.75% | 30.56% |
| Income Before Tax | -47.95% | -41.28% | -4.30% | 23.93% | 32.89% |
| Income Tax Expenses | 1,251.35% | 1,251.35% | 1,251.35% | 1,251.35% | -- |
| Earnings from Continuing Operations | -48.42% | -41.72% | -4.67% | 23.60% | 32.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -101.24% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.45% | -40.86% | -125.79% | -30.28% | -4.38% |
| EBIT | -41.39% | -33.50% | 0.75% | 23.75% | 30.56% |
| EBITDA | -- | -- | -- | -- | 80.58% |
| EPS Basic | -12.57% | -16.87% | -108.00% | -27.19% | -0.61% |
| Normalized Basic EPS | -9.04% | -13.62% | 7.51% | 25.69% | 33.99% |
| EPS Diluted | -12.28% | -16.56% | -106.83% | -26.92% | -0.53% |
| Normalized Diluted EPS | -9.04% | -13.62% | 7.51% | 25.69% | 33.99% |
| Average Basic Shares Outstanding | 43.12% | 21.46% | 7.64% | 1.94% | 2.63% |
| Average Diluted Shares Outstanding | 43.12% | 21.46% | 7.64% | 1.94% | 2.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |